Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/29549
Title: Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study
Authors: Luetkemeyer, Anne F
Rosenkranz, Susan L
Lu, Darlene
Grinsztejn, Beatriz
Sanchez, Jorge
Ssemmanda, Michael
Sanne, Ian
McIlleron, Helen
Havlir, Diane V
Haas, David W
Adult AIDS Clinical Trials Group A5221 Study Team
A5243 Study Team
Affilliation: University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
IMPACTA. Lima, Peru.
Joint Clinical Research Center. Kampala, Uganda.
University of the Witwatersrand. Faculty of Health Sciences. Johannesburg, South Africa.
University of Cape Town. Department of Medicine. Division of Clinical Pharmacology Cape Town, South Africa.
University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA.
Vanderbilt University School of Medicine. Department of Medicine. Nashville, Tennessee, USA.
Abstract: In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
Keywords: HIV/AIDS
Efavirenz
Pharmacogenetic
Rifampin
Tuberculosis
Issue Date: 2015
Citation: LUETKEMEYER, Anne F. et al. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-Based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, v. 60, n. 12, p. 1860–1863, 2015
DOI: 10.1093/cid/civ155
ISSN: 1058-4838
Copyright: restricted access
Appears in Collections:INI - Artigos de Periódicos



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.